Allison comes with a proven ability to develop effective clinical and regulatory strategies, lead global programmes, as highlighted by her role as VP Clinical R&D at publicly listed Prosensa Therapeutics BV (RNA modulation, ASO) as well as several achievements in late stage clinical management and early stage clinical scientific advice for first in man studies in neurology and rare-diseases. 

"We are thrilled to welcome Allison to the Sixfold Team” said Dr. Anna Perdrix Rosell, founder and co-CEO of Sixfold Bioscience.  “Allison has an exceptionally strong track record of leading oligonucleotide companies through the regulatory process, having led Prosensa's engagements with the FDA in early development and working with a variety of companies in early regulatory strategies, which have gone on to be hugely successful programs”. 

“Sixfold has built a very clear proposition for the delivery of therapeutic RNAs. I’m excited to be working with them on their clinical strategy and early scientific engagements” said Allison Morgan

Biography

Allison Morgan BSc is a clinical development scientist with over 30 years’ experience in the biopharmaceutical industry, undertaking both operational and senior executive roles internationally, including VP Clinical R&D at Prosensa, a therapeutic oligonucleotide company. Allison specialises in developing end-to-end clinical regulatory strategies from inception to registration, often in  complex and rare diseases lacking in precedent, requiring critical thinking and creative solutions to overcome scientific and regulatory constraints. Allison has extensive experience in interacting with regulators in US and Europe, as well as important academic and patient advocacy stakeholders, to achieve success

Sixfold Biosciences is a biotechnology company solving one of the most critical challenges preventing the greater utilization of powerful RNA medicines: delivery. Sixfold’s solution takes evolution as inspiration, learning and mimicking how RNA is naturally delivered to different cell types in the body. Using advanced AI and Bayesian Optimization, Sixfold is learning the language that encodes RNA-shuttle interactions and destination selection, unlocking new cell types for treatment.